BOTHELL, Wash., Feb. 2 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE Alternext US: DDD) today announced that the board of directors has appointed Bruce S. Morra, Ph.D., M.B.A., to serve as president and chief executive officer. Dr. Morra has served as a member of the SCOLR Pharma board of directors since August 2007.
Michael N. Taglich, Chairman of SCOLR Pharma's board of directors, said, "We are very pleased that Dr. Morra has agreed to become SCOLR Pharma's CEO. Since Dr. Morra's appointment to the board, he has been an able and trusted advisor. Given our longstanding belief that SCOLR's success will stem from maximizing opportunities for our proprietary CDT(R) technology in the pharmaceutical and over-the-counter arena, Dr. Morra's level of experience earned as an executive at numerous specialty pharmaceutical and healthcare companies coupled with his strategic alliance and business development expertise, makes him the right executive to assume leadership of our Company."
Dr. Morra has extensive experience in the pharmaceutical, medical device, biotechnology and polymers industries. Since 1998, Dr. Morra has been a Board Member and consultant for various public and private life science companies. He previously served as the President of West Pharmaceutical Services Drug Delivery and Contract Clinical Research businesses. Prior to this, Dr. Morra held several senior executive management positions including as Chief Business Officer of Progenitor Cell Therapy, as President, COO and CFO of Biopore Corporation and Polygenetics, Inc., as President, COO and Founder of Flamel Technologies, Inc's U.S. subsidiary, and as President of ISP Filters, a subsidiary of GAF Corporation. He received his B.S.E in Chemical Engineering from Princeton, a Ph.D. in Polymer Science and Engineering and an M.B.A. from the
Commenting on his appointment, Dr. Morra, said, "The b
|SOURCE SCOLR Pharma, Inc.|
Copyright©2009 PR Newswire.
All rights reserved